A Century After the Eugenics Movement, the U.S. Is Again Barring Disabled Immigrants
By Emma Cieslik,
Ms. Magazine
| 11. 20. 2025
A revived “public charge” standard directs officers to deny visas to people with disabilities, chronic illnesses and age-related conditions—echoing the exclusionary policies of the early 20th century.
Photo by The New York Public Library on Unsplash
This piece includes sanist slurs used in the late 19th and early 20th centuries.
This month, Secretary of State Marco Rubio instructed visa officers to consider obesity and other chronic health conditions, such as heart disease, cancer and diabetes, as justification to deny people visas to the United States. The guidance—along with direction that visa officers can reject visa applications for people beyond retirement age and if their dependents are elderly or disabled—is part of a “public charge” rulethat allows the government to deny visas and green cards if the person might use social welfare programs or be institutionalized.
Many were outraged and shocked, observing the Trump administration’s new expansion of the “public charge” rule—directing visa officers to deny entry to people with disabilities, chronic illnesses or age-related conditions—as a modern revival of eugenic immigration policy designed to exclude, control and institutionalize disabled and marginalized people. The “public charge” rule is not new, but this new definition seeks to restrict citizenship on the basis of possible institutionalization as the Trump...
Related Articles
By Emily Baumgaertner Nunn, The New York Times | 06.30.2026
A research program at the National Institutes of Health released the world’s largest database of human genomes and paired them with clinical data, officials announced Tuesday, paving the way for a new era of study in personalized medicine.
The All...
By Mustapha Bature Sallama, Modern Ghana | 06.11.2026
In much of West Africa, a woman who cannot bear children does not merely face a medical condition. She faces a verdict. Her marriage may unravel. Her community may turn cold. Her identity, in a social order that ties womanhood...
By Anna Rogers, Mother Jones | 06.19.2026
By Rebecca Simkin, BioNews | 06.29.2026
The US Food and Drug Administration (FDA) is allowing biotech company Regenxbio to reapply for licensing of a gene therapy for Hunter syndrome, in a reversal of its previous decision. Hunter syndrome, or mucopolysaccharidosis type II (MPS II), is a...